Eisai’s affiliates in China are wholly-owned by Eisai Co., Ltd. (Eisai), a Japanese multinational pharmaceutical company headquartered in Tokyo, with strong R&D capabilities.
Eisai has been smoothly developing its business in China since the early 1990s, starting with the establishment of Shenyang Eisai Pharmaceutical Co., Ltd. in 1991, followed by the establishment of Eisai Suzhou Pharmaceutical Co., Ltd, and was officially renamed Eisai China Inc. in 2002. With the development of its business in China, Eisai (Suzhou) Trading Co., Ltd. was in 2010 and Eisai China Holdings Ltd. was set up in 2014. In 2015, Eisai (Liaoning) Pharmaceutical Co., Ltd. was officially established through the full takeover of a local generic drug manufacturer. So far, a development mode has been formed, consisting of Eisai China Holdings Ltd. for capital control and management, while Eisai China Inc., Eisai (Liaoning) Pharmaceutical Co., Ltd. and Eisai (Suzhou) Trading Co., Ltd. for business support. In order to adapt to the rapid development of the business in China, the parenteral production facility and the new oral solid dose (OSD) production facility of Eisai China Inc. were completed respectively in November 2014 and November 2017. The production capacity of Eisai China has been rapidly increased.?
Currently, the total registered capital of Eisai China is USD 108.54 million. Eisai China promotes tens of pharmaceutical brands in China, specializing in neurology, oncology and gastrointestinal areas, and expands to the generic business.
In the future, the Suzhou Plant will not only meet the clinical needs for medication of Chinese patients, but also provide high-quality products to meet the needs of patients from other countries and regions in Asia. Besides, the sales volume of Eisai China has remained in the first position among the Japanese pharmaceutical enterprises in China for more than ten consecutive years.
|07/19/2019||LATEST TRENDS OF TREATMENT FOR ALZHEIMER’S DISEASE IN SESSIONS AND SYMPOSIUM AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019|
|07/19/2019||EISAI PRESENTS DATA SHOWING QUANTIFICATION OF TAU MICROTUBULE BINDING REGION IN CEREBROSPINAL FLUID AND THE IDENTIFICATION OF A TARGET ENGAGEMENT BIOMARKER FOR THE NEW ANTI-TAU ANTIBODY E2814 AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC)2019|
|07/18/2019||EISAI PRESENTS RESEARCH EVALUATING CORRELATION OF HIGHLY-PRECISELY MEASURED AMYLOID BETA IN PLASMA AND CEREBROSPINAL FLUID WITH NEWLY DEVELOPED AUTOMATED PROTEIN ASSAY SYSTEM AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019|
|07/18/2019||EISAI PRESENTS NONCLINICAL RESEARCH RESULTS OF ELENBECESTAT OF WITHOUT SIGNIFICANT EFFECTS ON SYNAPTIC FUNCTION IN BRAIN BY SPINAL DENSITIY EVALUATION AT EFFECTIVE DOSE TO DECREASE AMYLOID BETA LEVEL IN CEREBROSPINAL FLUID AT AAIC 2019|
|07/17/2019||ANTICANCER AGENT ERIBULIN MESYLATE APPROVED FOR TREATMENT OF LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN CHINA|